SCHEMBL20429583

SCHEMBL20429583

O=C(c1ccc(Cl)cc1)C(Br)c1cccc(I)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.42
MGLL Q99685 1/20 0.40
MDM2 Q00987 5/20 0.37
NTSR1 P30989 1/20 0.36
CES2 O00748 2/20 0.36
CES1 P23141 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
SLC6A2 P23975 2/20 0.36
SLC6A4 P31645 2/20 0.36
SLC6A3 Q01959 2/20 0.36
KCNH2 Q12809 2/20 0.36
KDM4E B2RXH2 1/20 0.35
GAA P10253 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
MDM4 O15151 1/20 0.35
TP53 P04637 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5318489 0.81 GSK3B (0.56) GSK3BMGLLMDM2CES2CES1
SCHEMBL627839 0.80 CES2 (0.53) NTSR1CES2CES1KDM4EGAA
SCHEMBL5339310 0.78 CES2 (0.48) GSK3BMDM2CES2CES1CYP2D6
SCHEMBL4016467 0.74 CES2 (0.52) NTSR1CES2CES1CYP2D6SLC6A2
SCHEMBL13178294 0.74 GSK3B (0.60) GSK3BCES2CES1CYP3A4CYP2D6
SCHEMBL7144713 0.73 CYP19A1 (0.53) CYP3A4KDM4EGAAALOX15TSHR
SCHEMBL5334151 0.72 KMT2A (0.53) GSK3BMGLLMDM2CES2CES1
SCHEMBL5319603 0.72 KMT2A (0.53) GSK3BMGLLMDM2CES2CES1
Bromide SCHEMBL6284312 0.72 CYP19A1 (0.51) CYP3A4KDM4EGAAALOX15TSHR
SCHEMBL10392108 0.71 MDM2 (0.47) MDM2CES2CES1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3459945-A1 BCL-2/BCL-XL INHIBITORS FOR USE IN THE TREATMENT OF CANCER The Regents of The University of Michigan (US) 2019-03-27 EP disclosed
EP-2668180-B1 BCL-2/BCL-XL INHIBITORS FOR USE IN THE TREATMENT OF CANCER UNIV MICHIGAN REGENTS (US) 2018-08-01 EP disclosed